Skip to content

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01536821
Acronym
PROGENI
Enrollment
81
Registered
2012-02-22
Start date
2011-05-31
Completion date
2013-12-31
Last updated
2013-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson disease, Parkinson's Disease, PD, LRRK2, genetics, genes

Brief summary

The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an affiliated research facility closest to their home.

Detailed description

Participants will be asked to complete a family history questionnaire, which will gather information about their family history of Parkinson's disease and related disorders. They will be asked to complete a single Study Visit, during which they will be asked to do some or all of the following: 1. Complete questionnaires regarding Parkinson's disease symptoms, medical history, mood, sleep, mental status, and activity level. 2. Be given a brief standard neurological examination. 3. Be given a scratch and sniff smell identification test. 4. Be asked to give a sample of approximately 2 tablespoons of blood. 5. Be asked to give a urine sample of approximately 1 tablespoon of urine.

Interventions

None listed

Sponsors

Michael J. Fox Foundation for Parkinson's Research
CollaboratorOTHER
Indiana University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Positive for a LRRK2 mutation

Design outcomes

Primary

MeasureTime frame
Observation and biological specimen collection1 time

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026